/
DARE
$2.10+$0.01 (+0.48%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$31.3M
15M shares
52-week range
$1.27 – $9.19
10% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.41%
Moderate
Price (6 mo)
Loading chart…
Change$-19.02
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $10.0M | $2.8M | $9.8K | $1.0M |
| Cost of revenue | $625.0K | $11.1K | $83.3K | $100.0K | $30.1M | $21.6M | $14.3M | $2.4M |
| Gross profit | −$2.4K | −$11.1K | −$83.3K | −$100.0K | −$20.1M | −$18.8M | −$14.3M | −$1.4M |
| Gross margin | — | — | — | — | -201.4% | -670.6% | -146110.2% | -137.5% |
| R&D | $6.4M | $8.5M | $20.8M | $30.6M | $30.0M | $21.5M | $14.2M | $5.52B |
| Operating income | −$16.9M | −$14.3M | −$27.4M | −$39.1M | −$31.4M | −$30.9M | −$23.5M | −$13.6M |
| EBITDA | −$11.7M | −$14.3M | −$27.4M | −$38.7M | −$30.9M | −$30.7M | −$4.0M | −$10.4M |
| Net income | −$16.7M | −$14.3M | −$27.4M | −$38.7M | −$30.9M | −$30.2M | −$4.1M | −$13.4M |
| Net margin | — | — | — | — | -309.5% | -1074.2% | -41430.9% | -1300.7% |
| EPS (diluted) | -30.16 | -10.99 | -10.93 | -7.52 | -4.39 | -4.15 | -0.48 | -1.20 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.95 | $-1.34–$-0.56 | 2 |
| 2027 | $7M | $-0.48 | $-0.62–$-0.38 | 1 |
| 2028 | $35M | $0.02 | $0.02–$0.03 | 1 |
| 2029 | $102M | $1.41 | $1.11–$1.82 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.18
Price
$2.10
Implied downside
-92%
Peer comparison
Dare Bioscience, Inc. Common Stock
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
www.darebioscience.com- Employees
- 24
- IPO / List date
- Apr 10, 2014
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds DARE.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 10,195 | $18.6K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-07-01 | 1-for-12reverse |
Recent trades on TradeandTell
No one on the platform has traded DARE yet.
